Prevalence of HBV in Pregnancy

Prevalence of Hepatitis B Virus Infection in Pregnancy

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT05442372

Enrollment

200

Registered

2022-07-05

Start date

2022-06-15

Completion date

2023-04-15

Last updated

2022-12-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatitis B

Keywords

Hepatitis B, Pregnancy, Prevalence

Brief summary

The most common mode of HBV transmission is materno-fetal transmission mainly during labor. This study aims to estimate the seroprevalence of HBV infection and the possible risk factors of HBV acquisition in pregnant women in Upper Egypt and to evaluate the predictive value of HBeAg and quantitative HBsAg as surrogate markers for high viremia in pregnant women.

Detailed description

Hepatitis B virus (HBV) is a cause of a vaccine-preventable life-threatening infection of the liver. Worldwide, the estimated number of cases of chronic HBV infection is 296 million cases with about 820 000 deaths, mostly due to liver cirrhosis and hepatocellular carcinoma. The prevalence of HBV infection among pregnant women is estimated to be 1.5-9.5%. The most important risk factor of materno-fetal transmission is high viremia. Other factors include hepatitis B e antigen (HBeAg) seropositivity, HBV S variant, and threatened preterm labor. Quantitative hepatitis B surface antigen (HBsAg) was postulated as a surrogate marker for HBV high viremia in pregnant women by many authors. This study aims to estimate the seroprevalence of HBV infection and the possible risk factors of HBV acquisition in pregnant women in Upper Egypt and to evaluate the predictive value of HBeAg and quantitative HBsAg as surrogate markers for high viremia in pregnant women.

Interventions

None listed

Study design

Observational model

CASE_ONLY

Time perspective

CROSS_SECTIONAL

Eligibility

Sex/Gender

FEMALE

Age

16 Years to 45 Years

Healthy volunteers

Inclusion criteria

* all pregnant women

Exclusion criteria

Design outcomes

Primary

Measure	Time frame	Description
HBsAg	6 months	HBsAg prevalence in pregnancy
Risk factors of HBV in pregnancy	6 months	Operations, blood transfusion, dental procedures, tattooing, family history of HBV

Secondary

Measure	Time frame	Description
correlation between HBeAg and quantitative HBsAg with viral load	6 months	to evaluate the predictive value of HBeAg and quantitative HBsAGg as surogate markers for high viraemia in pregnant women hbe ag

Countries

Egypt

Contacts

Primary ContactAmira Maher, MD

amiramaher@med.sohag.edu.eg01006789652

Outcome results